Ongoing Clinical Trials for Haemoptysis
Currently, there is 1 ongoing clinical trial investigating new treatments for haemoptysis, which involves coughing up blood from the lungs or airways. This trial is exploring the use of inhaled medications to quickly control bleeding during the early days of hospital treatment.
Clinical trial locations
Study on Tranexamic Acid and Terlipressin for Emergency Treatment of Mild to Severe Hemoptysis in Patients Without Cystic Fibrosis
This clinical trial is investigating two inhaled medications, tranexamic acid and terlipressin, for treating mild to severe haemoptysis. The study aims to determine how well these treatments can control bleeding during the first three days of hospitalization.
Main inclusion criteria:
- Adults between 18 and 90 years old
- Experiencing mild to severe haemoptysis for less than 7 days
- Total blood coughed up between 50 ml and 200 ml
- Admitted to the emergency department or ICU for less than 12 hours
- Must have social security affiliation
- Must sign informed consent to participate
- Women of childbearing potential must use effective contraception methods
Main exclusion criteria:
- Patients with cystic fibrosis are excluded from this trial
Trial focus and goals:
The trial focuses on the emergency treatment of haemoptysis through inhaled medications. Participants will be randomly assigned to receive either tranexamic acid, terlipressin, or a placebo administered through a nebulizer device. The main goal is to assess whether the bleeding stops completely or reduces significantly within three days without requiring additional medical procedures. Complete resolution means the bleeding stops entirely within three days, while partial resolution means the bleeding reduces to less than 50 ml within the first three days.
The study will monitor several important outcomes, including the total amount of blood coughed up, the need for further treatments such as bronchial artery embolization, and any side effects that may occur. Researchers will also track longer-term outcomes, including whether bleeding returns within 30 days and any adverse events such as heart problems or breathing difficulties.
Investigational drugs:
Tranexamic acid is being tested in an inhaled form. This medication helps control bleeding by preventing the breakdown of blood clots. It belongs to a class of drugs called antifibrinolytic agents, which work to stabilize blood clots and help stop bleeding in the lungs.
Terlipressin is also being evaluated in an inhaled form. This medication works differently by narrowing blood vessels, which reduces blood flow to the bleeding area and helps control the bleeding. It belongs to a class of drugs known as vasopressors, which are typically used to increase blood pressure and reduce bleeding.
Both medications are breathed in using a nebulizer device, making them easy to administer during emergency treatment. The trial is expected to continue until early 2026 and will provide valuable information about the effectiveness and safety of these treatments for managing haemoptysis.
Summary
This single ongoing trial represents an important investigation into emergency treatments for haemoptysis. The study is being conducted in France and focuses specifically on patients without cystic fibrosis. What makes this trial particularly interesting is its exploration of inhaled medications as a rapid treatment approach during the critical first three days of hospitalization. Both tranexamic acid and terlipressin work through different mechanisms to control bleeding, and the trial will help determine which approach, if any, is most effective. The use of inhaled medications offers the potential advantage of delivering treatment directly to the lungs where the bleeding occurs, which may provide faster relief compared to traditional treatments. Patients interested in participating should note that the trial has specific requirements regarding the timing and severity of bleeding, and those with cystic fibrosis are not eligible for this particular study.